Pharmaceutical compositions comprising glitazones and NRF2 activators
The invention relates to pharmaceutical compositions comprising PPAR agonists and Nrf2 activators and methods of using combinations of PPAR agonists and Nrf2 activators for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis.
1. A method of alleviating multiple sclerosis or a clinical symptom thereof or delaying the onset of multiple sclerosis or a clinical symptom thereof in a patient, comprising the co-administration of therapeutically effective amounts of an Nrf2 activator selected from the fumaric acid esters and salts thereof and a PPAR gamma agonist selected from glitazones and salt forms thereof to said patient.
2. The method according to claim 1 , wherein the glitazone is selected from the group of pioglitazone and its salt forms and rosiglitazone and its salt forms.
3. The method according to claim 1 , wherein the glitazone is pioglitazone.
4. The method according to claim 1 , wherein the glitazone is pioglitazone hydrochloride.
5. The method according to claim 1 , wherein the Nrf2 activator is selected from the group of monoalkyl fumarates and dialkyl fumarates.
6. The method according to claim 1 , wherein the Nrf2 activator is selected from the group of monomethyl fumarate, dimethyl fumarate, monoethyl fumarate and diethyl fumarate.
7. The method according to claim 1 , wherein the PPAR gamma agonist is rosiglitazone.
8. The method according to claim 1 , wherein the PPAR gamma agonist is rosiglitazone maleate.
9. The method according to claim 1 , wherein said co-administration is an oral administration.